Frank Kondrad - Neurobo Pharmaceuticals VP Devel
| NRBO Stock | USD 2.37 0.02 0.85% |
Insider
Frank Kondrad is VP Devel of Neurobo Pharmaceuticals
| Address | 545 Concord Avenue, Cambridge, MA, United States, 02138 |
| Phone | 857 702 9600 |
| Web | https://www.neurobopharma.com |
Neurobo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.7435) % which means that it has lost $0.7435 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6076) %, meaning that it created substantial loss on money invested by shareholders. Neurobo Pharmaceuticals' management efficiency ratios could be used to measure how well Neurobo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to -0.57. In addition to that, Return On Capital Employed is likely to drop to -0.99. As of the 25th of November 2024, Net Tangible Assets is likely to grow to about 17.6 M, while Total Assets are likely to drop about 18.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| MD MBA | Kiora Pharmaceuticals | 50 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Quan Vu | 180 Life Sciences | 52 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Jason Assad | 180 Life Sciences | N/A | |
| MD DrSc | Allarity Therapeutics | 81 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Chester III | Revelation Biosciences | 44 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Joan Brown | Allarity Therapeutics | 70 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Professor MD | Allarity Therapeutics | 67 | |
| Meeshanthini Dogan | Cardio Diagnostics Holdings | 35 | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| Steen Knudsen | Allarity Therapeutics | 63 | |
Management Performance
| Return On Equity | -1.61 | ||||
| Return On Asset | -0.74 |
Neurobo Pharmaceuticals Leadership Team
Elected by the shareholders, the Neurobo Pharmaceuticals' board of directors comprises two types of representatives: Neurobo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurobo. The board's role is to monitor Neurobo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Neurobo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurobo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| PharmD BCPS, VP Operations | ||
| Marshall Woodworth, Principal CFO | ||
| HyungHeon Kim, President CEO | ||
| Robert Homolka, Senior Operations | ||
| Ben MD, CEO Pres | ||
| Frank Kondrad, VP Devel | ||
| MiKyung Kim, Chief Officer |
Neurobo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurobo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.61 | ||||
| Return On Asset | -0.74 | ||||
| Current Valuation | (1.1 M) | ||||
| Shares Outstanding | 8.62 M | ||||
| Shares Owned By Insiders | 65.23 % | ||||
| Shares Owned By Institutions | 12.71 % | ||||
| Number Of Shares Shorted | 19.2 K | ||||
| Price To Earning | (1.44) X | ||||
| Price To Book | 1.58 X | ||||
| Revenue | 7 K |
Pair Trading with Neurobo Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurobo Stock
| 0.64 | ME | 23Andme Holding | PairCorr |
| 0.84 | VALN | Valneva SE ADR | PairCorr |
| 0.77 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Neurobo Stock
| 0.77 | KZR | Kezar Life Sciences | PairCorr |
| 0.53 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.37 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Return On Assets (0.74) | Return On Equity (1.61) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.